[3] Taro (the name of the company was derived from the Hebrew words for "pharmaceutical industry") was founded in 1950 by a team of pharmacists and physicians in Haifa, Israel.

In 1952 it was acquired by United States-based investors and began production and marketing Rokal and Rokacet pain relievers.

In 2006, Taro was delisted from NASDAQ, after it had to restate financial results downwards for the years 2004, 2005 and 2006 [5] In 2010, Sun Pharmaceuticals of India acquired a majority stake in the company.

[9] In February 2009, the US Food and Drug Administration (FDA) released a warning letter to Taro Pharmaceuticals pointing out some issues relating to the company's manufacturing facility in Brampton, Ontario, Canada.

[10] In February 2011, Taro Pharmaceuticals resolved the warning letters after a re-inspection from FDA which showed an acceptable regulatory status.